Microbix mobilizes SWATT team to help companies worldwide expand flu vaccine production

15-Aug-2007

Microbix Biosystems Inc. is establishing a Special Workgroup for Applied technology transfer (SWATT) that shall be instrumental in helping manufacturers significantly boost the amount of flu vaccine produced throughout the world.

The SWATT team will be sent to facilities adopting the Microbix proprietary virus yield enhancement technology - VIRUSMAX(TM). The team is expected to be operational this Fall. It will spend several weeks in each location helping customers implement the technology and training local personnel.

At present, only about 350 million doses of flu vaccine are produced annually in the world. There are only three countries that produce enough vaccine domestically to immunize their populations - Canada, France, and Australia. Every other country lacks the manufacturing capacity to meet its own needs. The largest domestic deficits are the U.S., China and India.

According to the company, Microbix' technology has been proven to double vaccine production output. It was also announced that Australia has indicated that it will issue a patent on this technology to Microbix. Similar patent protection has already been allowed in the U.S., Canada and India, and a number of other applications in major markets are currently pending.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Gene Bridges Announces Distribution Agreement with CAMBIO for Red/ET Recombination Kits

Modeling NAFLD with human pluripotent stem cell derived immature hepatocyte like cells

Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor - Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research

Vitamins doing gymnastics: Scientists capture first full image of vitamin B12 in action - Work by University of Michigan and MIT team yields new understanding of crucial reaction in the body and in CO2-scrubbing bacteria

Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis

Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets

Stanford researchers explore link between human birth defect syndrome, cancer metastasis

Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan

Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition

Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology